Landos Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Landos Biopharma

21/03/2024 13:32

* Landos Biopharma Inc  LABP.OQ  reported a quarterly
adjusted
loss of 99 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-1.30.  The mean expectation of two analysts
for the quarter was for a loss of 91 cents per share. Wall
Street expected results to range from -92 cents to -91 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Landos Biopharma Inc's reported EPS for the quarter was a
loss
of 99 cents​.
    * The company reported a quarterly loss of $6.12 million.
    * Landos Biopharma Inc shares had risen by 91.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Landos Biopharma
Inc is $5.00 
This summary was machine generated from LSEG data March 21 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.91          -0.99          Missed
 Sep. 30 2023      -0.88          -0.94          Missed
 Jun. 30 2023      -1.10          -0.63          Beat
 Mar. 31 2023      -0.95          -0.90          Beat